Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBIX Stock Forecast 2026-2027
$133.25
Current Price
$13.40B
Market Cap
Buy 23
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to NBIX Price Targets
+88.1%
To High Target of $250.65
+38.8%
To Median Target of $185.00
+5.1%
To Low Target of $140.00
NBIX Price Momentum
+5.5%
1 Week Change
+4.4%
1 Month Change
+31.4%
1 Year Change
-6.0%
Year-to-Date Change
-16.8%
From 52W High of $160.18
+34.7%
From 52W Low of $98.95
📊 TOP ANALYST CALLS
Did NBIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neurocrine is one of their latest high-conviction picks.
Latest NBIX Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, NBIX has a bullish consensus with a median price target of $185.00 (ranging from $140.00 to $250.65). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $133.25, the median forecast implies a 38.8% upside. This outlook is supported by 23 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Danielle Brill at Truist Securities, suggesting a 5.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBIX Analyst Ratings
23
Buy
4
Hold
0
Sell
NBIX Price Target Range
Low
$140.00
Average
$185.00
High
$250.65
Current: $133.25
Latest NBIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Maintains | $185.00 |
| Apr 7, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $242.00 |
| Apr 7, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $166.00 |
| Apr 7, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $215.00 |
| Apr 7, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $200.00 |
| Apr 6, 2026 | Needham | Ami Fadia | Buy | Reiterates | $185.00 |
| Mar 12, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $177.00 |
| Feb 24, 2026 | Wolfe Research | Rudy Li | Outperform | Initiates | $160.00 |
| Feb 17, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $140.00 |
| Feb 17, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $176.00 |
| Feb 13, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $175.00 |
| Feb 12, 2026 | RBC Capital | Brian Abrahams | Outperform | Maintains | $177.00 |
| Feb 12, 2026 | Needham | Ami Fadia | Buy | Maintains | $185.00 |
| Feb 12, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $192.00 |
| Feb 12, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $204.00 |
| Feb 12, 2026 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $140.00 |
| Feb 12, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $151.00 |
| Jan 23, 2026 | UBS | Ashwani Verma | Buy | Maintains | $178.00 |
| Jan 12, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $177.00 |
| Jan 8, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $169.00 |
Neurocrine Biosciences Inc. (NBIX) Competitors
The following stocks are similar to Neurocrine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurocrine Biosciences Inc. (NBIX) Financial Data
Neurocrine Biosciences Inc. has a market capitalization of $13.40B with a P/E ratio of 28.5x. The company generates $2.86B in trailing twelve-month revenue with a 16.7% profit margin.
Revenue growth is +28.3% quarter-over-quarter, while maintaining an operating margin of +28.2% and return on equity of +16.4%.
Valuation Metrics
Market Cap
$13.40B
Enterprise Value
$12.36B
P/E Ratio
28.5x
PEG Ratio
0.6x
Price/Sales
4.7x
Growth & Margins
Revenue Growth (YoY)
+28.3%
Gross Margin
+97.8%
Operating Margin
+28.2%
Net Margin
+16.7%
EPS Growth
+49.1%
Financial Health
Cash/Price Ratio
+11.1%
Current Ratio
3.4x
Debt/Equity
14.5x
ROE
+16.4%
ROA
+9.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neurocrine Biosciences Inc. (NBIX) Business Model
About Neurocrine Biosciences Inc.
What They Do
Biopharmaceutical company focused on neuroscience treatments.
Business Model
Neurocrine Biosciences generates revenue through the development and commercialization of innovative biopharmaceuticals for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA, is a key revenue driver, while partnered products and a diverse pipeline of investigational therapies further enhance its business model.
Additional Information
The company has a strong presence in the neuroscience sector with products addressing tardive dyskinesia and Huntington's disease. Collaborations with major pharmaceutical companies such as AbbVie and a mid-to-late-stage pipeline aimed at various psychiatric and metabolic conditions indicate significant growth potential. Founded in 1992 and located in San Diego, California, it is well-positioned in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,000
CEO
Mr. Kyle W. Gano Ph.D.
Country
United States
IPO Year
1996
Website
www.neurocrine.comNeurocrine Biosciences Inc. (NBIX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?
Investors need to pay close attention to NBIX stock based on the movements in the options market latel.
Apr 15, 2026
By Zacks Equity Research
Tale of the Tape
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
Apr 08, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
5 days ago
Quick Summary
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will hold a conference call and webcast on May 5, 2026, at 1:30 p.m. PT to discuss its Q1 2026 financial results.
Why It Matters
Neurocrine's upcoming conference call will reveal Q1 2026 financial results, critical for assessing performance and potential stock movement.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Neurocrine Biosciences reported that INGREZZA (valbenazine) demonstrated higher long-term treatment continuation and lower medication switching compared to AUSTEDO XR in adults with tardive dyskinesia.
Why It Matters
Higher treatment persistence for INGREZZA over AUSTEDO XR suggests a competitive advantage, potentially boosting Neurocrine Biosciences' market position and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Recent activity in the options market suggests that investors should closely monitor NBIX stock for potential volatility or significant movements.
Why It Matters
Increased options activity on NBIX stock may signal heightened investor interest or volatility, potentially impacting stock price and trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Nxera Pharma (TSE 4565) will receive $22.5 million in milestone payments from Neurocrine Biosciences following the start of a Phase 2 study for NBI-1117570 in schizophrenia. Revenue recognized in Q1 FY2026.
Why It Matters
Nxera Pharma's milestone payment of $22.5 million boosts its revenue and financial stability. Positive clinical developments for NBI-1117570 could enhance its market valuation and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Soleno Therapeutics stock is rising in premarket trading following reports that Neurocrine is close to acquiring the company.
Why It Matters
Soleno Therapeutics' stock surge reflects potential acquisition interest from Neurocrine, signaling increased valuation and strategic consolidation in the biotech sector.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Neurocrine Biosciences (NBIX) held an M&A call, discussing strategic acquisitions and partnerships to enhance its portfolio and growth opportunities. Further details can impact investor sentiment.
Why It Matters
Neurocrine's M&A activities could signal strategic growth plans, impacting stock performance and market positioning, which are crucial for investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About NBIX Stock
What is Neurocrine Biosciences Inc.'s (NBIX) stock forecast for 2026?
Based on our analysis of 38 Wall Street analysts, Neurocrine Biosciences Inc. (NBIX) has a median price target of $185.00. The highest price target is $250.65 and the lowest is $140.00.
Is NBIX stock a good investment in 2026?
According to current analyst ratings, NBIX has 23 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $133.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBIX stock?
Wall Street analysts predict NBIX stock could reach $185.00 in the next 12 months. This represents a 38.8% increase from the current price of $133.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurocrine Biosciences Inc.'s business model?
Neurocrine Biosciences generates revenue through the development and commercialization of innovative biopharmaceuticals for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA, is a key revenue driver, while partnered products and a diverse pipeline of investigational therapies further enhance its business model.
What is the highest forecasted price for NBIX Neurocrine Biosciences Inc.?
The highest price target for NBIX is $250.65 from at , which represents a 88.1% increase from the current price of $133.25.
What is the lowest forecasted price for NBIX Neurocrine Biosciences Inc.?
The lowest price target for NBIX is $140.00 from Danielle Brill at Truist Securities, which represents a 5.1% increase from the current price of $133.25.
What is the overall NBIX consensus from analysts for Neurocrine Biosciences Inc.?
The overall analyst consensus for NBIX is bullish. Out of 38 Wall Street analysts, 23 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $185.00.
How accurate are NBIX stock price projections?
Stock price projections, including those for Neurocrine Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 6:38 PM UTC